Most drug launches are decided before the first doctor sees the brand

Melonie WarfelChief Commercial Officer, SwishX·8 min read
Contents
  1. Introduction
  2. The launch scoreboard has barely moved in a decade
  3. More launches, narrower markets, less room to start slow
  4. A launch runs on three clocks, and the slowest one sets the pace
  5. The content clock is the one nobody can start early
  6. The shortage is the right answer, not more content
  7. Europe runs the same race on a longer track
  8. Three questions to ask a year before approval

Launch performance has barely improved in a decade, and a slow start rarely recovers. The constraint has moved from awareness to readiness, and the slowest step is turning approved evidence into approved materials.

We talk about drug launches as if they begin on approval day. The evidence says most of them are decided before it. IQVIA's launch research finds that 80% of launches continue on the trajectory set in their first six months for the next five years, and almost everything that shapes those six months is settled in the year before the first doctor sees the brand.

For most of the industry's history, the launch problem was awareness: get the message in front of enough prescribers, often enough, faster than the competitor. That problem has not vanished, but it is no longer the binding constraint. The constraint now is readiness, meaning whether the evidence, the access story and the approved materials are all ready to work on day one, in every channel a specialist actually uses. And the slowest part of readiness is rarely the science. It is turning approved evidence into approved materials, usually against a label that arrives late.

The launch scoreboard has barely moved in a decade

The numbers vary with the method, but the shape is consistent. McKinsey's 2014 analysis found that about two-thirds of new drugs missed their pre-launch consensus forecasts in year one, and that those falling short typically kept under-delivering for the next two years. Deloitte's study of 149 US launches from 2012 to 2017 found a milder 36% miss rate in year one, and that about 70% of products that missed at launch kept missing in later years.

Recent cohorts look no better. Trinity Life Sciences found that 50% of the 2023 US launch class underperformed its pre-launch first-year forecast, against 54% across launches from 2020 to 2023. ZS, tracking 69 US first launches from 2018 to 2024, found the share missing original analyst expectations rose from 40% in the launch year to 65% two years later.

The fair objection is that this is a story about forecasts as much as launches. Analysts are optimistic, consensus numbers anchor on the best case, and ZS itself notes that some forecasts are simply too high. I accept that. But a bad forecast does not explain persistence. If misses were noise, a good share would recover. The pattern across all of these studies is that a slow start tends to stay slow, which tells me the first months do real damage rather than merely exposing a bad estimate.

More launches, narrower markets, less room to start slow

The volume keeps rising while the markets get narrower. IQVIA counted 79 novel active substances launched globally in 2025, 53 of them in the US, and expects 70 to 80 a year over the next five years. Of the 46 novel drugs FDA's drug center approved in 2025, half carried orphan drug designation. Specialty medicines already accounted for 54% of US medicine spending in IQVIA's 2024 analysis.

Each of those facts compresses the window. A rare-disease brand may have a small number of treating physicians, and the first impression it makes on them is most of its market. An oncology launch arrives in a tumor type where several mechanisms compete for the same line of therapy and the same tumor boards. And all of them are trying to reach specialists who are harder to see than ever: Veeva reported in 2024 that 45% of US HCPs were accessible to biopharma field teams, down from 60% eighteen months earlier.

In a primary-care launch of the old kind, a slow first quarter could be overcome with more reps, more samples and more share of voice. In a specialty launch, physicians form a view of the brand from the first few interactions, and that view travels through tumor boards, congress hallways and referral networks. There is no second first impression to buy.

A launch runs on three clocks, and the slowest one sets the pace

The frame I find most useful is to think of a launch as three clocks that start at different times. The evidence clock covers the data, publications, congress presence and medical education that convince a physician the drug works for their patients. The access clock covers the value story for payers and HTA bodies, the contracting and the patient support that let a willing physician get the drug to the patient. The content clock covers every approved piece a rep, a website, an email or a speaker uses to say the right thing about the drug.

The industry has learned to start the first two early. Medical teams engage specialists long before approval, and the data says it pays: in a Veeva analysis of US oncology drugs, companies that invested more in pre-launch scientific activity saw 40% faster treatment adoption, and field medical engagement with key opinion leaders before launch improved adoption by 50%. Access has had its own reckoning. Deloitte found that half of the products that missed first-year forecasts had market access problems, and few brand teams now leave the payer story until filing.

The content clock is different. It cannot really start until the label is close to final, it runs in sequence through medical, legal and regulatory review, and it has to finish for every channel at once. So it tends to be the clock that decides whether the brand can actually say, on day one, what the evidence and access teams prepared it to say.

The content clock is the one nobody can start early

The mechanics are worth spelling out. Under PDUFA VII, FDA's late-cycle meeting with the sponsor, where the review team walks through the remaining issues, generally happens no later than three months before the goal date for a standard review and two months for a priority one. The final label text is typically one of the last things settled after that. Every asset built before then rests on what the team expects the label to say.

When the final text differs, even by a phrase, the change runs through the claims, the charts, the safety information and every format derived from them. A narrower population or a new warning is not an edit to one asset. It is an edit to all of them, and each one goes back through review.

For some products the content clock is also a regulatory gate. For drugs and biologics approved under accelerated approval, FDA's rules require promotional materials intended for the first 120 days after approval to be submitted during the pre-approval review, and later materials at least 30 days before first use. A launch on that pathway is not ready until its materials are, however strong the data looks.

The tactical side of this, working back from the PDUFA date, is covered in our launch content checklist. The strategic point is simpler. If the content clock starts last and runs in sequence, then the speed of MLR review and the ability to rework a library quickly when the label lands are launch capabilities, not back-office functions. Most launch plans still budget them as the latter.

The shortage is the right answer, not more content

You would expect a constraint on content to show up as too little content. It shows up as the opposite. Veeva's 2025 Pulse data found that field teams use content in fewer than half of HCP meetings, and that nearly 80% of what is approved is rarely or never used. The same data shows content-driven engagement more than doubles treatment adoption. So the industry produces approved material in volume, most of it sits idle, and the material that would move a physician goes underused.

My reading is that these facts describe one problem. Launch content is usually planned as a list of deliverables: the core visual aid, the website, the email series, the speaker deck. Specialists do not experience a brand as a list of deliverables. They experience it as answers to their questions: whether it works in their patients with a given comorbidity, how it compares with what they use now, what the prior authorization will need, and what to watch for in month two. A brand is ready when it has an approved, on-label answer to each of those, in each channel, on the day the physician asks.

Seen that way, the scarce asset at launch is not a polished detail aid. It is the approved answer to the hard question, available wherever the question comes up and kept in step with the label when it changes. This is the part of the problem we work on at SwishX, so weigh my view with that in mind. I would hold it anyway: brands that plan launch content around the questions physicians actually ask spend less time producing pieces nobody opens.

There is a people side too. An approved answer is only useful if the rep or MSL can deliver it well under pressure, and a completed certification is not the same thing.

Europe runs the same race on a longer track

Outside the US the clocks run longer, and the access clock dominates. EFPIA's W.A.I.T. data, published in May 2026, put the median time from authorization to availability at 532 days across European countries, ranging from 56 days in Germany to 1,201 in Romania. Only 28% of medicines were fully covered by public reimbursement, compared with 42% in 2019.

The EU's HTA Regulation adds a new dependency. Since 12 January 2025, new cancer medicines and advanced therapies authorized through EMA have been included in joint clinical assessment at EU level, with orphan medicines following from 2028 and all new medicines from 2030. In practice that pulls the evidence package for European payers closer to the regulatory filing, and turns the comparators and endpoints chosen years earlier into a launch decision in every member state.

The second-order effect lands on sequencing and content. A brand that launches in the US first, then Germany, then other markets in waves runs a separate content clock in each, against labels that do not always match. The discipline is the same everywhere: tie every claim to the label section it depends on, so a difference in one market's label tells you exactly which materials change. Companies that build that once will reach their next market faster than those that restart the content clock from zero.

Three questions to ask a year before approval

If I were sitting with a launch team twelve months out, I would set the readiness dashboard aside and ask three questions.

First, if the label comes back narrower than we hope, how many days until every channel says the new thing? If the honest answer is that nobody knows, the content clock is your critical path, and it deserves the same scenario planning the forecast gets. Decide in advance what each plausible label means for the headline claims, and hold anything slow and expensive until the text is final.

Second, can our field and medical teams answer the ten hardest questions a specialist will ask in the first month, on label, and how do we know? Write those questions down now. They should drive the content plan, the training plan and the MLR queue, in that order.

Third, does every payer and HTA body we care about have the evidence in the form it needs, on the date it needs it? In the US that means a value story ready at filing. In Europe it now means the joint clinical assessment dossier as well, alongside the national submissions that still decide price.

Then treat MLR capacity as launch capacity. Staff it, plan it and measure it the way you would a manufacturing line before launch, because in practice that is what it is.

By the time the first doctor sees the brand, most of the launch has already been decided. The only question is whether you decided it on purpose.

Filed underPerspectives

Keep reading

All articles

Want to see Magic Studio on your brand?

Video, visual aids, ads, approved email and web, made from your approved claims and ready for MLR review.